- $5.81m
- -$5.76m
Annual balance sheet for Transcode Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.828 | 20.8 | 4.98 | 2.77 | 5.81 |
| Net Total Receivables | — | — | 0.36 | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 0.831 | 22.7 | 7.38 | 4.46 | 7.09 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 0.206 | 0.209 | 0.602 | 0.089 |
| Other Long Term Assets | |||||
| Total Assets | 1.06 | 22.9 | 7.59 | 5.17 | 7.29 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.405 | 2.53 | 4.35 | 3.49 | 2.77 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.46 | 2.53 | 4.35 | 3.53 | 9.31 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -3.41 | 20.4 | 3.24 | 1.64 | -2.02 |
| Total Liabilities & Shareholders' Equity | 1.06 | 22.9 | 7.59 | 5.17 | 7.29 |
| Total Common Shares Outstanding |